Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
XinThera
San Diego, California, United States
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
XinThera developed precision small molecule inhibitors of PARP1 for oncology (including solid and brain cancers) and MK2 for inflammatory and autoimmune diseases. Lead assets remained at preclinical stage at time of Gilead acquisition, with potential to address unmet needs in oncology and inflammation and anticipated to enter the clinic after acquisition. No clinical efficacy or safety results have been reported.[2][6]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on XinThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XinThera.